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Ikaros, a transcription factor encoded by IKZF1 gene, plays es-
sential role in lymphocyte development [1]. Alternative splicing
regulates the function of Ikaros, resulting in the production of at
least 13 different isoforms. Long isoforms (Ik1–3) are able to bind
DNA and considered to be functional. Short isoforms (Ik4–10) are
not efﬁcient to bind DNA, and function in a dominant-negative
(DN) manner [2,3]. Several studies have shown that focal IKZF1
deletions are frequent genetic alterations in acute lymphoblastic
leukemia (ALL) [4–6]. All IKZF1 mutations in ALL are loss-of-
function, resulting in null Ikaros, haplosufﬁcient or DN phenotype
[7]. Focal IKZF1 deletions in ALL are supposed to be a reason for
expression of short, non-DNA-binding Ikaros isoforms which
switch their localization in the cell from nucleus to cytoplasm.
IKZF1 deletions were ﬁrst discovered as frequent genetic lesion in
BCR-ABL1 positive ALL [8], proved to be a marker of poor prog-
nosis in general ALL group [9,10] and BCR-ABL1 negative ALL [11].
IKZF1 deletions are different from most oncogenes that may occur
in leukemic subclones [12,13].
Presented case describes a BCR-ABL1-negative B-cell precursor
ALL (BP-ALL) patient with clonal evolution of IKZF1 genotype
during disease treatment and progression. Due to the fact that
IKZF1 alterations were not taken into account for risk stratiﬁca-
tion, poor prognosis of the patient has been underestimated.
2. Case report
2.1. Clinical data
The patient was a 17-year-old male who initially presented
with weakness, fewer and lymphadenopathy. He was noted tox.doi.org/10.1016/j.lrr.2016.06.005
89/& 2016 The Authors. Published by Elsevier Ltd. This is an open access article u
esponding author.
ail address: vshyukova@gmail.com (V. Vshyukova).have leukocytosis (21.6109/l) with 75% blasts in the peripheral
blood. Clonal karyotype, clinical and blast cell features were es-
tablished. The blast count in the bone marrow (BM) at the time of
diagnosis was 84.0%. Immunophenotyping of BM cells showed 79%
blasts expressing HLA-DR, 78% - CD20, 98% blasts were positive
with CD19, and 99% – with CD10. It was also noted that 98% cells
expressed CD34 and CD22. Based on morphology and im-
munophenotyping, the patient was diagnosed as BP-ALL, L2, FAB
and common B.
Routine BM cytogenetic analysis revealed normal male kar-
yotype (46, XY), however metaphases were not suitable for ana-
lysis by G-banding.
A multiplex, nested reverse transcription PCR assay for 16 of
the most common ALL-associated chromosomal rearrangements
(BCR/ABL1, SIL1/TAL1, E2A/PBX, TEL/AML1, and MLL transloca-
tions) was negative.
The patient was stratiﬁed into standard risk group (SRG), and
started the induction therapy according to the multicenter trial
ALL-Moscow/Berlin (ALL-MB)2002 chemotherapy regiment in
children with ALL (randomization№1: dexamethasone 6 mg/m2 p.
o., daunorubicin 45 mg/m2 on 8th day). After completing of the
induction the patient underwent the 3 stages of consolidation [14].
On day 15 of the induction the BM evaluation was character-
ized as residual ALL with blasts count more than 1%. The BM
evaluation after induction revealed no evidence of residual ALL
(0.01–0.09% of blasts in the BM, and less than 0.01% before con-
solidation I). The patient was consolidated with three additional
cycles of chemotherapy and achieved complete remission with a
normal complete blood count (CBC) and transfusion in-
dependence. According to ALL-MB-2002 regiment the patient was
not a candidate for allogeneic BM transplantation due to standard
risk of recurrence.
Twenty-six months later, he presented with early combined BM
and central nervous system relapsed ALL. His CBC showed white
blood cells count (WBC) of 46.1109/l with 90% blasts. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was 92%. Flow cytometry as well as reverse transcription PCR
showed similar results to those at diagnosis. Repeated routine
cytogenetic analysis revealed the 46,? dup(X)(p11.2p22.1)Y, der(9)t
(9;?)(p13;?),? del(14)(q13q23) [9]/47, idem,þmar[3] complex
chromosome abnormality. The relapse initially was classiﬁed as
S2-risk and treated according to the ALL relapse protocol (ALL-REZ
2002) of the Berlin/ Frankfurt/ Münster (BFM) group [15]. At the
postinduction day 10 (F2-blosk), disease was complicated with
prolonged neutropenia, Gram-negative sepsis, right-focal con-
ﬂuent pneumonia and oxygen lack. Despite appropriate treatment
and resuscitation procedures within 48 h, patient died from septic
shock and multiple organ failure on the 13th day of postinduction
(F2-blosk).
2.2. PCR analysis and sequencing of intragenic IKZF1 deletions
Genomic DNA was isolated from the BM mononuclear cells
using the phenol-chloroform extraction. Most common IKZF1 de-
letions of exons 1–6 (ΔEx1–6) and 3–6 (ΔEx3–6) were screened by
PCR: Used primers were recommended by Liu P. et al [16]. except
ΔEx1–6_F, that we selected ourselves (Supplementary table 1).
PCR was performed using 100 ng of DNA in a 30 mL reaction under
the following conditions: 35 cycles of 30 s at 94 °C, 30 s at 62 °C
and 1 min at 72 °C, with a ﬁnal extension step of 5 min at 72 °C.
PCR products were primarily examined by 1.5% agarose gel elec-
trophoresis. Bands were puriﬁed from agarose gel and sequenced
on ABI PRISM 3130 Genetic analyzer (Applied Biosystems, USA) for
junction identiﬁcation.
At the diagnosis, two different IKZF1 deletions were detected:
ΔEx3–6d and ΔEx1–6. At the relapse another one Ex3–6r deletion
was found (Fig. 1).
2.3. Relative quantity PCR (RQ-PCR) analysis of Ikaros isoforms
expression
We estimated expression of all IKZF1 isoforms at the diagnosis
by RQ-PCR with settled set of primers and probes relative to
control gene (Abelson tyrosine kinase, ABL) expression (un-
published data, Supplementary table 2). DN isoforms Ik6, 9 and 10
were overexpressed at diagnosis, BM sample at relapse was not
available for RNA extraction.
2.4. Fluorescence in situ hybridization (FISH) analysis
Fixed mononuclear BM cells from the patient at diagnosis and
at relapse, as well as control ALL BM samples were analyzed for
interphase FISH according to manufacturer recommendations. TheFig. 1. Sequences of junctional regions of three different IKZF1 deletions in BM cells gen
solid line, probes – the dotted line. Intron sequences before and after the deletion breakp
of the references to color in this ﬁgure legend, the reader is referred to the web versioncommercial repeat-free probe Sure FISH 7p12.2 IKZF1 128 kb RD
(Agilent Dako, USA) was used. Following the probe hybridization
process, cells nuclei were identiﬁed by DAPI II staining (Abbott
Laboratories, Illinois, USA). A minimum of 200 interphase cells
were analyzed separately for each probe using the OLYMRUS BX52
microscope (Olympus, USA), equipped with appropriate ﬁlters,
and coupled to a BioView automated loader systems and software
(BioView Ltd., Israel). Digital images were obtained by the use of
charge-coupled device camera provided with the microscope:
Orange Red (purple), and DAPI II (blue) ﬂuorescence signals were
recorded separately, merged and contented.
Control samples showed over 95% of cells with two signals
representing both normal IKZF1 alleles, 2.5% with one, and 2.5%
with three signals, demonstrating a method error level of 5%. 70%
of patient's BM cells at diagnosis showed deletion of one IKZF1
allele and 26% cells brought both normal alleles. In the BM at re-
lapse 59% of cells were heterozygous for the IKZF1 deletions and
33% of cells with normal alleles were observed (Fig. 2).
2.5. Localization of Ikaros protein
We examined the subcellular localization of Ikaros protein in
patient's BM cells at diagnosis and control ALL BM cells (with wild
type IKZF1 gene). Mononuclear BM cells were ﬁxed in fresh so-
lution of 4% paraformaldehyde at 37 °C for 15 min, washed 2 times,
permeabilized in 0.2% Triton-X100 for 10 min at room tempera-
ture, washed 2 times. Then PE Mouse Anti-Human Ikaros antibody
(BD Pharminogen, USA) was used to stain the cells as re-
commended by manufacturer. Finally, nuclei were stained by in-
cubating with 0.1 μg/ml propidium iodide (PI) (37 °C, 20 min) and
visualized by laser confocal microscope (Leica DM2500, USA).
Anti-Ikaros antibody (green, ﬂuorescence excitation maximum of
488 nm and emission maximum of 578 nm) and PI (red, ﬂuores-
cence excitation maximum of 535 nm and the emission maximum
of 617 nm) ﬂuorescence signals were recorded separately and
merged.
IKZF1 wild type leukemic cells demonstrated nuclear localiza-
tion of Ikaros, whereas in patient's blasts DN isoforms of Ikaros
protein localized predominantly in cytoplasm due to the deletion
of DNA-binding domain on the N-term of the protein (Fig. 3).
2.6. RQ-PCR-based MRD detection by clonal Ig/TCR gene
rearrangements
Quantitative assessment of minimal residual disease (MRD)
was performed by RQ-PCR using patient-speciﬁc primer for two
identiﬁed clonal T-cell receptors and immunoglobulin gene re-
arrangements (IgH and TCRG) as described previously [17]omic DNA of the patient. Positions of primers used for RQ-PCR are underlined by a
oint colored in green and blue, non-matrix nucleotides – in red. (For interpretation
of this article.)
Fig. 2. iFISH analysis of IKZF1 gene, objectives at 100x magniﬁcation. Purple ﬂuorescence signals marked IKZF1 locus, the nuclei stained with DAPI II (blue). One separate
purple signal indicates lack of IKZF1 (intragenic deletion). (1–3) Diagnosis; (46) Relapse; (79) Control BM cells from patient with IKZF1 wild type. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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triplicates using serial dilutions (101, 102, 103, 104, 105) of
patient's DNA in normal polyclonal DNA. MRD level was calculated
relative to the diagnostic material.
MRD level was counted in 4 time points between diagnosis and
relapse. The ﬁrst follow up sample on day 15 of induction was
positive (more than 1%), following with two negative points. Two
month before the relapse MRD level remained negative, whereas
at relapse both targets were positive (Table 1).
2.7. RQ-PCR-based MRD detection by IKZF1 gene deletions
To reveal clonal evolution of IKZF1 deletions from diagnosis to
relapse, patient-speciﬁc primers were designed to IKZF1 deletedjunction. RQ-PCR analysis was performed with consensus second
primer and probe (previously described for ΔEx3–6) [18]. Ex-
perimental set up was the same as for MRD analysis by Ig/TCR.
We found out that both IKZF1 deletions ΔEx3–6d and ΔEx1–6,
diagnosed at the ﬁrst disease presentation, persisted at induction,
and then disappeared the same way as Ig/TCR targets. Another
IKZF1 deletion ΔEx3–6r detected at relapse was found also at the
initial diagnosis and induction on the level of a few percents
(Table 1).
3. Discussion
The presence of IKZF1 mutations was conﬁrmed by several
methods directed to different levels of manifestation: at the
Fig. 3. Confocal microscopy was used to examine the localization of wild-type and mutant Ikaros proteins. Nuclei stained with propidium iodine (PI, red), and Ikaros proteins
were visualized by PE Mouse Anti-Human Ikaros antibodies (green), objectives at 100x magniﬁcation. Micron scale 10 mm. (13) Abnormal cytoplasmic compartmentalization
patterns of Ikaros protein (green) in patient's BM cells at diagnosis; (46) Nuclear localization of Ikaros protein (green) in control ALL BM cells. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Measurement of clonal genetic targets by RQ-PCR during follow-up.
ΔEx3-6d ΔEx3-6r ΔEx1-6 IgH TCRG
diagnosis 1 8.74E-02 1 1 1
induction 4.75E-02 1.22E-02 1.1 2.44E-02 3.25E-01
consolidation II 0 0 0 0 0
consolidation III 0 0 0 0 0
2 month before relapse 0 0 0 0 0
relapse 0 1 0 9.7E-02 1.57E-01
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tection), and protein (cellular localization of Ikaros protein) levels.
Coding sequence of IKZF1 gene was not screened for point
mutations due to the absence of its clinical relevance in ALL. Fur-
thermore, according to the data announced in COSMIC, point
mutations in IKZF1 coding sequence are mutually exclusive ge-
netic events with ΔEx3-Ex6 and ΔEx1-Ex6 as well.
Generally, three different intragenic IKZF1 deletions were
found in the patient by PCR: ΔEx3–6d and ΔEx1–6 at diagnosis
and ΔEx3-Ex6r at relapse. Ex3-Ex6r deletion was also revealed in
minor leukemic subclone at diagnosis by means of RQ-PCR with
patient-speciﬁc primer at a lower level (0.087). FISH analysis in-
dicated all deletions as heterozygous. These results can be ex-
plained by the presence of three clones of leukemic cells, differ in
IKZF1 genotype. Two major clones caring ΔEx3–6d and ΔEx1–6
ﬁnally were eliminated during treatment, however minor ΔEx3-
Ex6r clone retained and led to early relapse. This case clearly de-
monstrated that clonal heterogeneity by IKZF1 gene status andclonal selection during the treatment took place. It is important to
note that leukemic cells at diagnosis and relapse were positive for
the same IgH and TCRG rearrangements, which proves that all
leukemic clones were of common origin, and IZKF1 deletions are
not initial, but secondary events. IKZF1 deletion is deﬁnitely bound
to disease progression, as far as large majority of the cells were
IKZF1 deleted at diagnosis, and 26 months later at relapse. So, this
or that deletion required for retaining leukemic phenotype and
progression. It might appear that mutant ΔEx3-Ex6r IKZF1 dele-
tion minor at the diagnosis itself provide to the cells sufﬁcient
proliferative or drug resistance advantage. However, to our mind,
Ex3-Ex6r IKZF1 deletion itself does not provide more aggressive
phenotype, than Ex3-Ex6d or Ex1-Ex6 deletions, because all of
them resulting in the expression of short Ikaros isoforms with
identical dominant-negative phenotype. We assume that minor
ΔEx3-Ex6r clone acquired additional genetic lesion during the
treatment.
Our results show that IKZF1 deletions could be used as a target,
but reliability of MRD analysis may be impaired by instability of
this marker during disease progression.
In primary diagnosis IKZF1 status was not taken into account
for risk group stratiﬁcation. According to protocol ALL-MB-2002
regulations, risk was underestimated and patient was assigned to
the SRG. Prognostic value of IKZF1 alterations in ALL, especially
BCR-ABL1 negative ALL, is still debated [19]. This case demon-
strated the importance of screening of IKZF1 deletions for ALL
prognosis.
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Our report suggests the screening of IKZF1 gene alterations at
diagnosis might be sufﬁcient for prognosis of ALL, especially for
BCR-ABL1 negative patients. IKZF1 gene abnormalities can be an
independent genetic event which is not initiated by BCR-ABL1
fusion oncogene. In this described case, IKZF1 clonal deletion was
the only predictor of relapse and poor prognosis.
From the diagnostic point of view, the analysis of IKZF1 gene
deletions is complicated by different localization of chromosome
breakpoints. Such methods as SNP-arrays [8,20], CGH-arrays [6,21]
and MLPA [22–24] were mostly used for the analysis of this locus.
However, the PCR detection is also applicable in most cases and
can be supplemented by iFISH, RQ-PCR evaluation of short iso-
forms expression or protein localization by ﬂuorescent
microscopy.
In contrast to the classic chromosomal translocations in ALL,
such as BCR-ABL1 or TEL-AML1, which are stable, IKZF1 deletions
tend to oligoclonality and demonstrate clonal evolution in the
disease progression. This makes IKZF1 deletions less reliable tar-
gets for MRD monitoring as compared with clonal Ig/TCR
rearrangement.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.lrr.2016.06.005.References
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